PLRX Should I Buy
-
$
0.000
0.000(0.000%)
At close0.000(0.000%)Aft-market
ET
Pliant Therapeutics Inc (PLRX) is not a strong buy for a beginner, long-term investor with $50,000-$100,000 available for investment. The stock lacks clear positive signals from technical, options, and financial perspectives. While hedge funds are increasing their positions, the company's financial performance is weak, and the stock's short-term trend indicates limited upside potential. The lack of significant catalysts, both technical and fundamental, suggests holding off on investment at this time.
The MACD is slightly positive at 0.011 but contracting, indicating weakening momentum. RSI at 61.277 is neutral, and moving averages are converging, suggesting no clear trend. The stock is trading near its pivot level of 1.27, with resistance at 1.312 and support at 1.228. Overall, the technical indicators do not signal a strong buying opportunity.
Hedge funds have increased their buying activity by 138.46% over the last quarter. The company is shifting its focus to oncology, with promising early Phase I data for PLN-101095 showing significant tumor reduction.
Insiders are neutral, with no significant trading activity. The company's financial performance is weak, with a significant drop in net income (-54.47% YoY) and EPS (-54.74% YoY). The stock's short-term trend indicates limited upside potential, with a 20% chance of a -0.36% change in the next day and -1.76% in the next week.
In Q3 2025, the company reported no revenue growth (0.00% YoY) and a significant decline in net income (-54.47% YoY) and EPS (-54.74% YoY). Gross margin remained at 0, showing no improvement.
No specific analyst rating or price target changes were provided. However, the lack of strong financial performance and limited positive catalysts likely weigh on analyst sentiment.
